Mesenchymal Stem Cell Activity Evaluation via Adenylate Kinase 4
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for culturing mesenchymal stem cells for clinical use fail to ensure sufficient quality and quantity due to decreased activity over time and varying culture conditions, leading to the inclusion of aged and dead cells, which can result in inadequate therapeutic agents for liver dysfunction.
Innovation Solution
A method involving the collection, isolation, and culturing of mesenchymal stem cells, followed by assaying the amount of adenylate kinase 4 to determine their activity level, allowing for the evaluation and selection of cells suitable for therapeutic use or subculturing, thereby ensuring the quality and quantity required for clinical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If mesenchymal stem cells are cultured to a desired amount through primary culturing and subculturing, then the quantity of cells is increased, but the activity (quality) of the cells decreases due to aging and varying culture conditions
Solution Approach 1:
The invention measures adenylate kinase 4 levels before clinical use to predict cell activity in advance. This preliminary assessment allows selection of cells with sufficient activity before they are administered, preventing the use of aged or low-quality cells that would result from extended culturing
Solution Approach 2:
The invention introduces a feedback mechanism by measuring adenylate kinase 4 levels to monitor cell quality during the culturing process. This feedback allows for quality control decisions about whether cells have maintained sufficient activity levels despite proliferation, enabling selection of high-quality cells for clinical use
2Reliability
If direct clinical use of mesenchymal stem cells from bone marrow aspirates is performed, then the activity level is maintained, but a large amount of cells must be collected which is a heavy burden for the living body
Solution Approach 1:
The invention enables preliminary assessment of cell activity through adenylate kinase 4 measurement, allowing clinicians to determine whether collected cells have sufficient quality for therapy before administration. This ensures that even after culturing and proliferation, the cells maintain therapeutic effectiveness, reducing the need to collect excessively large amounts of cells from the patient
3Quantity of substance
If subculturing is performed to proliferate mesenchymal stem cells, then the quantity of cells increases, but the culture conditions vary among containers leading to inconsistent cell quality
Solution Approach 1:
The invention introduces quality monitoring feedback by measuring adenylate kinase 4 levels in cells from different culture containers. This allows identification and selection of containers that produced cells with consistent, high-quality characteristics, enabling uniformity control across multiple subculture operations
Solution Approach 2:
The invention uses adenylate kinase 4 level measurement as a quality parameter to assess and compare cells from different culture conditions. By establishing threshold values for acceptable activity levels, the method enables selection of cells that meet uniform quality standards regardless of which specific culture container they originated from
Data Source
AI summary
A method for evaluating the activity level of mesenchymal stem cells, and a method for culturing mesenchymal stem cells using the evaluation method in the field of culturing mesenchymal stem cells for regenerative medicine, and further, a method for producing a therapeutic agent for liver dysfunction and a therapeutic agent for liver dysfunction. This method for evaluating mesenchymal stem cell activity has an assay step for assaying the amount of adenylate kinase 4 (AK4) in the mesenchymal stem cells; and a determination step for determining the activity level of the mesenchymal stem cells from the assayed amount of adenylate kinase 4.